作为结核病辅助治疗的P-葡萄糖蛋白抑制剂
Kishan Kumar Parida1, Monali Lahiri1, Mainak Ghosh1
1Department of Biological Sciences (Pharmacology and Toxicology), National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India.
Drug discovery today
|July 20, 2024
概括
耐多药结核病 (MDR-TB) 是一个主要的挑战,通常是由P-glycoprotein (P-gp) 和血管生成等排泄驱动的. 抑制这些因素可能会改善药物输送,缩短结核病治疗时间.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 耐多药结核病 (MDR-TB) 构成了重大的治疗挑战.
- 排泄的升级,特别是P-糖蛋白 (P-gp) 和血管生成,有助于MDR-TB.
- P-gp阻碍了药物的生物可用性,而血管生成则使药物输送到结核病颗粒瘤变得复杂.
研究的目的:
- 审查P-gp和血管生成对MDR-TB有所贡献的机制.
- 探索P-gp抑制剂和抗血管原药在改善结核病治疗中的潜力.
- 讨论缩短结核病治疗时间的辅助疗法.
主要方法:
- 关于P-gp,血管生成及其在结核病中的作用的现有文献的综述.
- 在结核病模型中研究P-gp抑制剂 (例如,维拉帕米尔) 和抗血管性药物 (例如,贝瓦西祖马布) 的研究分析.
- 讨论这些干预措施对药物输送和治疗结果的综合影响.
主要成果:
- 结核病感染对P-gp表达和血管生成因子进行上调.
- 结合P-gp和抗血管新生策略,有望提高药物输送到颗粒瘤的效果.
- P-gp 抑制剂和抗血管原体药物已显示出改善结核病药物的生物可用性和疗效的潜力.
结论:
- 准P-gp和血管生成是对抗MDR-TB的有希望的战略.
- 使用P-gp抑制剂的辅助治疗可能会缩短结核病治疗的持续时间.
- 对结合治疗方法的进一步研究是有必要的,以克服MDR-TB的挑战.
相关概念视频
01:28Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
01:29Pulmonary Tuberculosis I
228
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
228
01:26Pulmonary Tuberculosis IV
134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
01:27Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
01:28Pneumonia IV: Management
317
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
317
01:28Pulmonary Tuberculosis II
215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215